| This week's sponsor is Bracket. | |  | |
Featured Story Tuesday, February 21, 2017  Sarepta has struck a $125 million deal to sell a voucher it got with last year’s controversial FDA approval of its new Duchenne drug to Gilead, which will give the Big Biotech a one-time speedy review pass for an NDA app to the U.S. regulator.
Tuesday, February 21, 2017 Pfizer said the FDA has given its experimental leukemia med inotuzumab ozogamicin a priority review as it gets to work on assessing the medication for approval, which could come as early as August. Thursday, January 26, 2017 Among the many meds that’ll lose patent protection in the U.S. this year are 10 drugs that each contribute in a big way for top drugmakers. Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead Sciences are set to hit the patent cliff this year with some of their respective big sellers. Tuesday, February 21, 2017 From startups to leading global companies, Greater Fort Lauderdale provides a stimulating and supportive business environment for success in the life sciences. Tuesday, February 21, 2017 Nordic Nanovector CEO Luigi Costa has talked up the level of third-party interest in non-Hodgkin lymphoma candidate Betalutin. Costa claimed the level of interest in the asset is growing as clinical data accumulates, triggering a double-digit jump in Nanovector’s stock price. Tuesday, February 21, 2017 Cidara Therapeutics will stop work on its antifungal CD101 in women with moderate-to-severe acute vulvovaginal candidiasis (VVC), after the topical candidate failed in a mid-stage trial. Tuesday, February 21, 2017 VBL Therapeutics has presented more data from a phase 2 trial of VB-111 monotherapy in thyroid cancer patients. The release adds evidence of dose response to support the previously-reported difference in progression-free survival between the low and high-dose cohorts. Friday, February 17, 2017 Scientists at Emory University’s Winship Cancer Institute are on a mission to unlock the mysteries of lung cancer cells that have long been thought to be unresponsive to any drug therapy. So they’ve developed what they call a “spiderweb of interactions” between proteins in those cancer cells, and they’re using the data to figure out how to target cancer mutations in the lung. Tuesday, February 21, 2017 Celgene’s late-stage pill, ozanimod, could hit $2 billion in sales and add pressure to an already competitive oral MS market, analysts say. | This week's sponsor is RAPS. | |  | |
| | | Trevena had posted late-stage data showing that just some doses of its opioid painkiller were found as effective as morphine, while it outperformed a placebo, but its shares traded down 34% this morning on the news. Release Valeant has struck an R&D deal with EyeGate for a licensing agreement on an EGP-437 combo product in post-op pain and inflammation in ocular surgery patients. Statement The FDA has given Cell Medica's leading cancer immunotherapy candidate its coveted fast track tag. Release | |
|
Resources Presented By: Veeva Share your thoughts on the life sciences industry’s progress in reducing system and process complexity to improve study execution. The first 50 qualified respondents will receive a $10 Amazon gift card, as well as a $10 donation made to Doctors Without Borders in their name. Finish the survey today! Sponsored By: Veeva Learn over a dozen best practices for deploying a global content system. Read Whitepaper. Sponsored By: Veeva Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper. Sponsored By: Veeva Learn How to Create a Unified RIM Environment for IDMP. Find out. Sponsored By: Veeva The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Sponsored By: Salesforce Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform. | 
